Tagrisso (osmertinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Instructions: Please fill out all applicable sections completely and legibly. Attach any additional documentation that is important for the review (e.g., chart notes or lab data, to support the authorization request). Information contained in this form is Protected Health Information under HIPAA.

☐ **URGENT**

MEMBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PHONE NUMBER:	**DATE OF BIRTH:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
PATIENT INSURANCE ID NUMBER:	

☐ **MALE** ☐ **FEMALE** **HEIGHT (IN/CM):** _____ **WEIGHT (LB/KG):** _____ **ALLERGIES:** _____

IF YOU ARE NOT THE PATIENT OR THE PRESCRIBER, YOU WILL NEED TO SUBMIT A PHI DISCLOSURE AUTHORIZATION FORM WITH THIS REQUEST WHICH CAN BE FOUND AT THE FOLLOWING LINK: PRIMETHERAPEUTICS.COM/NOPP

PATIENT'S AUTHORIZED REPRESENTATIVE (IF APPLICABLE): _____
AUTHORIZED REPRESENTATIVE'S PHONE NUMBER: _____

PRESCRIBER INFORMATION	
LAST NAME:	**FIRST NAME:**
PRESCRIBER SPECIALTY:	**EMAIL ADDRESS:**
NPI NUMBER:	**DEA NUMBER:**
PHONE NUMBER:	**FAX NUMBER:**
STREET ADDRESS:	
CITY:	**STATE:** **ZIP CODE:**
REQUESTER (if different than prescriber):	**OFFICE CONTACT PERSON:**

MEDICATION OR MEDICAL DISPENSING INFORMATION			
MEDICATION NAME:			
DOSE/STRENGTH:	**FREQUENCY:**	**LENGTH OF THERAPY/REFILLS:**	**QUANTITY:**
☐ **NEW THERAPY** ☐ **RENEWAL** **IF RENEWAL:** DATE THERAPY INITIATED: DURATION OF THERAPY (SPECIFIC DATES):			

Continued on next page

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company

Tagrisso (osmertinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

1. HAS THE PATIENT TRIED ANY OTHER MEDICATIONS FOR THIS CONDITION? ☐ **YES** (if yes, complete below) ☐ **NO**		
MEDICATION/THERAPY (SPECIFY DRUG NAME AND DOSAGE)**:**	**DURATION OF THERAPY** (SPECIFY DATES)**:**	**RESPONSE/REASON FOR FAILURE/ALLERGY:**

2. LIST DIAGNOSES:	**ICD-10:**
☐ **Primary Non-small cell lung cancer (NSCLC)** ☐ **Metastatic Non-small cell lung cancer (NSCLC** ☐ **Leptomeningeal disease(LMD)** ☐ Other diagnosis: _____ ICD-10 Code(s):	

3. REQUIRED CLINICAL INFORMATION: PLEASE PROVIDE ALL RELEVANT CLINICAL INFORMATION TO SUPPORT A PRIOR AUTHORIZATION.

Is patient going to be using drug in combination with a clinical trial? ☐ **Yes** ☐ **No**

Does the patient's tumor harbor an EGFR exon 19 deletion or an exon 21 L858R mutation? □ **Yes** □ **No** ***Please submit the tumor genetic analysis.***

Does the patient's tumor harbor an EGFR exon mutation of any kind? □ **Yes** □ **No** ***Please submit the tumor genetic analysis.***

<u>For diagnosis of primary non-small cell lung cancer, answer the following</u>:
Is patient's tumor stage 1B, II, or IIIA? □ **Yes** □ **No** ***Please submit documentation.***

Has patient undergone COMPLETE surgical resection of the primary NSCLC? □ **Yes** □ **No** ***Please submit documentation*.**

Were all surgical margins of the resection negative for tumor? □ **Yes** □ **No** ***Please submit pathology report*.**

Has patient undergone radiation therapy? □ **Yes** □ **No**

Has patient received any prior anticancer treatment(s)(including any chemotherapy or any EGFR-TKI agent(s))? □ **Yes** □ **No** ***Please submit documentation*.**

<u>For diagnosis of metastatic non-small cell lung cancer, anwer the following</u>:
Will Tagrisso be used as first-line? □ **Yes** □ **No**

Will Tagrisso be used with chemotherapy? □ **Yes** □ **No** ***Please submit documentation*.**

Will Tagrisso be used without chemotherapy? □ **Yes** □ **No** ***Please submit documentation*.**

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company

Tagrisso (osmertinib)
Prior Authorization Request Form

Caterpillar Prescription Drug Benefit
Phone: 877-228-7909 Fax: 800-424-7640

MEMBER'S LAST NAME: _____ **MEMBER'S FIRST NAME:** _____

Will Tagrisso be used in combination with pemetrexed and a platinum-based chemotherapy for advanced disease? □ Yes □ No

<u>For diagnosis of leptomeningeal disease, answer the following</u>:

Does patient have metastasis to the brain? □ Yes □ No **Please submit documentation*
Has the patient progressed on Tagrisso(osmertinib) and developed leptomeningeal disease? □ Yes □ No **Please submit documentation.*

Renewal Request:
Is patient continuing to demonstrate a positive clinical response? □ Yes □ No Please submit documentation.

Are there any other comments, diagnoses, symptoms, medications tried or failed, and/or any other information the physician feels is important to this review?

_____

_____

Please note: Not all drugs/diagnosis are covered on all plans. This request may be denied unless all required information is received.

ATTESTATION: I attest the information provided is true and accurate to the best of my knowledge. I understand that the Health Plan, insurer, Medical Group or its designees may perform a routine audit and request the medical information necessary to verify the accuracy of the information reported on this form.

Prescriber Signature or Electronic I.D. Verification: _____ **Date:** _____

CONFIDENTIALITY NOTICE: The documents accompanying this transmission contain confidential health information that is legally privileged. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or action taken in reliance on the contents of these documents is strictly prohibited. If you have received this information in error, please notify the sender immediately (via return FAX) and arrange for the return or destruction of these documents.

FAX THIS FORM TO: 800-424-7640
MAIL REQUESTS TO: Prime Therapeutics Management Prior Authorization Program
Attn: CP-4201
P.O. Box 64811
St. Paul, MN 55164-0811
Phone: 877-228-7909

©2017-2024 Prime Therapeutics Management LLC, a Prime Therapeutics company
Prime Therapeutics Management – Commercial Clients. Revision Date: 11.15.2025
CAT009